On the other hand, the expression of MTMR2 was decreased in breast invasive carcinoma (BRCA), kidney chromophobe (KICH), acute myeloid leukemia (LAML), lung adenocarcinoma (LUAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC) (Fig. 1A). Here, MTMR2 is linked to invasive breast carcinoma.